首页|期刊导航|Oncology Research|First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer:A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up
First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer:A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up
Xi Qin Yulan Liu Lin Zhu Yunyan Mo Jing Zhang Zhuchun Jiang Dongning Huang Xinrong Hu Jingzhang Li Quanfang Chen Feng Xue
Oncology Research2025,Vol.33Issue(9):P.2451-2462,12.
Oncology Research2025,Vol.33Issue(9):P.2451-2462,12.DOI:10.32604/or.2025.064119
First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer:A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up
摘要
关键词
Aumolertinib/non-small cell lung cancer(NSCLC)/safety/epidermal growth factor receptor(EGFR)/real world分类
医药卫生引用本文复制引用
Xi Qin,Yulan Liu,Lin Zhu,Yunyan Mo,Jing Zhang,Zhuchun Jiang,Dongning Huang,Xinrong Hu,Jingzhang Li,Quanfang Chen,Feng Xue..First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer:A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up[J].Oncology Research,2025,33(9):P.2451-2462,12.基金项目
supported by the National Natural Science Foundation of China(grant nos.82260498 and 82160471) (grant nos.82260498 and 82160471)
Quzhou City Qujiang District Life Oasis PublicWelfare Service Center,Health Development Promotion Project-Cancer Research Project(grant no.BJHA-CRP-033) (grant no.BJHA-CRP-033)
Guangxi Medical and Health Key Discipline Construction Project,2021 Guilin City Science Research and Technology Development Plan Project(grant no.20210227-7-9) (grant no.20210227-7-9)
Beijing Xisike Clinical Oncology Research Foundation(grant no.Y-QL202101-0214). (grant no.Y-QL202101-0214)